

Supplementary data

Supplementary table 1: Review of studies on cluster 2-related PPGL

RET			
Author, year of publication (Ref.)	Total cases	Malignant PPGL	Prevalence
Van Heerden et al, 1990 (1)	9	0	-
Vasen et al, 1992 (2)	8	0	-
Laimore et al, 1993 (3)	58	0	-
Casanova et al, 1993 (4)	100	3	3%
Bonnin et al, 1994(5)	10	1	10%
Proye et al, 1994(6)	41	2	4.9%
Modigliani et al, 1995 (7)	300	12	4%
Eng et al, 1995(8)	5	0	-
Lee et al, 1996 (9)	12	0	-
Gagner et al, 1996(10)	8	2	25%
Iihara et al, 1997(11)	132	2	1.5%
Masmiquel et al, 1997(12)	5	2	40%
Pomares et al, 1998(13)	23	0	-
De Graaf et al, 2000(14)	17	0	-
Inabnet et al, 2000(15)	15	1	6.7%
Nguyen et al, 2001 (16)	14	0	-
Burnt et al, 2002(17)	19	0	-
Yip et al, 2004 (18)	46	0	-
Patocs et al, 2004(19)	7	0	-
Asari et al, 2006(20)	17	0	-
Zhou et al, 2007(21)	30	5	16.7%
Rodriguez et al, 2008 (22)	54	0	-
Mannelli et al, 2009(23)	27	0	-
Frank-Raue et al, 2011 (24)	54	0	-
Iacobone et al, 2011(25)	4	0	-
Scholten et al, 2011(26)	61	0	-
Qi et al, 2012(27)	21	0	-
Machens et al, 2013(28)	84	1	1.2%
Thosani et al, 2013 (29)	85	0	-
Imai et al, 2013 (30)	212	2	0.94%
Castinetti et al, 2014 (31)	563	2	0.35%
Korpershoek et al, 2014(32)	18	0	-
Crona et al, 2014(33)	13	1	7.7%
Ferreira et al, 2014(34)	14	0	-
Lee et al, 2015(35)	7	1	1.2%
Lang et al, 2015(36)	67	2	3.0%

Zhao et al, 2015(37)	8	0	-
Rajan et al, 2016 (38)	17	0	-
Puar et al, 2016(39)	8	0	-
Kotecka-Blicharz et al, 2016(40)	41	1	2.4%
Mucha et al, 2017 (41)	85	0	-
Sriphrapadang et al, 2017(42)	5	0	-
Pamporaki et al,2017(43)	46	2	4.3%
Sbardella et al, 2018 (44)	6	1	0.17%
Stenman et al, 2018 (45)	10	0	-
Makri et al, 2019 (46)	8	0	-
Castinetti at al, 2019 (47)	153	4	2.6%
Kittah et al, 2020 (48)	49	2	4.1%
Ma et al, 2020(49)	12	1	8.3%
Our center	23	2	8.7%
Total	2631	52	2%
NF1			
Patocs et al, 2004(19)	4	0	-
Amar et al, 2005 (50)	13	1	7.8%
Bausch et al, 2006 (51)	25	3	12%
Mannelli et al, 2009(23)	11	0	-
Zinnamosca et al, 2011 (52)	7	0	-
Iacobone et al, 2011(24)	4	0	-
Scholten et al, 2011(26)	22	0	-
Shinall et al, 2014 (53)	6	0	-
Kepenekian et al, 2016 (54)	12	0	-
Puar et al, 2016(39)	4	0	-
Moramarco et al, 2017 (55)	9	0	-
Gruber et al, 2017 (56)	41	2	4.9%
Pamporaki et al,2017(43)	19	1	5.2%
Sbardella et al, 2018 (44)	6	0	-
Petr et al, 2018 (57)	17	2	11.8%
Sharefi et al, 2019 (58)	27	2	7.4%
Kittah et al, 2020 (48)	8	0	-
Our center	5	1	20%

Total	240	12	5%
TMEM127			
Qin et al, 2010 (59)	16	0	-
Yao et al, 2010 (60)	20	1	5%
Neumann et al, 2011 (61)	2	0	-
Takeichi et al, 2012 (62)	2	0	-
Abermil et al, 2012 (63)	6	0	-
Lefebvre et al, 2012(64)	5	2	40%
Toledo et al, 2015 (65)	11	0	-
Patocs et al, 2016(66)	3	0	-
Bausch et al, 2017 (67)	29	3	10.3%
Eijkelenkamp et al, 2018 (68)	2	0	-
Armaiz-Pena et al, 2021 (69)	30	0	-
Total	126	6	4.8%
MAX			
Comino-Méndez et al, 2011 (70)	12	3	25%
Burnichon et al, 2012 (71)	23	2	8.7%
Korpershoek et al, 2016 (72)	3	1	33%
Bausch et al, 2017 (67)	11	0	-
Daly et al, 2018 (73)	3	1	33%
Ma et al, 2020(49)	6	2	33.3%
Seabrooke et al, 2021 (74)	8	2	25%
Total	66	11	16.7%

References:

- 1 Heerden JA van, Roland CF, Carney JA, Sheps SG & Grant CS. Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s). *World Journal of Surgery* 1990 **14** 325–329. (<https://doi.org/10.1007/BF01658516>)
- 2 Vasen HF, Feltz M van der, Raue F, Kruseman AN, Koppeschaar HP, Pieters G, Seif FJ, Blum WF & Lips CJ. The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases. *Archives of Internal Medicine* 1992 **152** 1250–1252.
- 3 Lairmore TC, Ball DW, Baylin SB & Wells SA. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. *Annals of Surgery* 1993 **217** 595–601; discussion 601-603. (<https://doi.org/10.1097/00000658-199306000-00001>)

- 4 Casanova S, Rosenberg-Bourgin M, Farkas D, Calmettes C, Feingold N, Heshmati HM, Cohen R, Conte-Devolx B, Guillausseau PJ & Houdent C. Pheochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 cases. *Clinical Endocrinology* 1993 **38** 531–537. (<https://doi.org/10.1111/j.1365-2265.1993.tb00350.x>)
- 5 Bonnin F, Schlumberger M, Gardet P, Tenenbaum F, Lumbroso J, Leclere J, Comoy E, Megnigbeto A, Travagli JP & Parmentier C. Screening for adrenal medullary disease in patients with medullary thyroid carcinoma. *Journal of Endocrinological Investigation* 1994 **17** 253–257. (<https://doi.org/10.1007/BF03348970>)
- 6 Proye CA, Vix M, Jansson S, Tisell LE, Dralle H & Hiller W. ‘The’ pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? *World Journal of Surgery* 1994 **18** 467–472. (<https://doi.org/10.1007/BF00353738>)
- 7 Modigliani E, Vasen HM, Raue K, Dralle H, Frilling A, Gheri RG, Brandi ML, Limbert E, Niederle B & Forgas L. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. *Journal of Internal Medicine* 1995 **238** 363–367. (<https://doi.org/10.1111/j.1365-2796.1995.tb01211.x>)
- 8 Eng C, Crossey PA, Mulligan LM, Healey CS, Houghton C, Prowse A, Chew SL, Dahia PL, O’Riordan JL & Toledo SP. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic pheochromocytomas. *Journal of Medical Genetics* 1995 **32** 934–937. (<https://doi.org/10.1136/jmg.32.12.934>)
- 9 Lee JE, Curley SA, Gagel RF, Evans DB & Hickey RC. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. *Surgery* 1996 **120** 1064–1070; discussion 1070-1071. ([https://doi.org/10.1016/s0039-6060\(96\)80056-0](https://doi.org/10.1016/s0039-6060(96)80056-0))
- 10 Gagner M, Breton G, Pharand D & Pomp A. Is laparoscopic adrenalectomy indicated for pheochromocytomas? *Surgery* 1996 **120** 1076–1079; discussion 1079-1080. ([https://doi.org/10.1016/s0039-6060\(96\)80058-4](https://doi.org/10.1016/s0039-6060(96)80058-4))
- 11 Iihara M, Yamashita T, Okamoto T, Kanbe M, Yamazaki K, Egawa S, Yamaguchi K & Obara T. A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan. *Japanese Journal of Clinical Oncology* 1997 **27** 128–134. (<https://doi.org/10.1093/jjco/27.3.128>)
- 12 Masmiquel L, Castro-Forns M, Torres I de, García A, Vidal MT & Simó R. Leu-M1 immunoreactivity and pheochromocytoma. *Journal of Clinical Pathology* 1997 **50** 168–170. (<https://doi.org/10.1136/jcp.50.2.168>)
- 13 Pomares FJ, Cañas R, Rodríguez JM, Hernández AM, Parrilla P & Tebar FJ. Differences between sporadic and multiple endocrine neoplasia type 2A pheochromocytoma. *Clinical Endocrinology* 1998 **48** 195–200. (<https://doi.org/10.1046/j.1365-2265.1998.3751208.x>)
- 14 De Graaf JS, Dullaart RP, Kok T, Piers DA & Zwierstra RP. Limited role of meta-iodobenzylguanidine scintigraphy in imaging pheochromocytoma in patients with multiple endocrine neoplasia type II. *The European Journal of Surgery = Acta Chirurgica* 2000 **166** 289–292. (<https://doi.org/10.1080/110241500750009104>)

- 15 Inabnet WB, Caragliano P & Pertsemlidis D. Pheochromocytoma: inherited associations, bilaterality, and cortex preservation. *Surgery* 2000 **128** 1007-1011;discussion 1011-1012. (<https://doi.org/10.1067/msy.2000.110846>)
- 16 Nguyen L, Niccoli-Sire P, Caron P, Bastie D, Maes B, Chabrier G, Chabre O, Rohmer V, Lecomte P, Henry JF, *et al.* Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study. *European Journal of Endocrinology* 2001 **144** 37–44. (<https://doi.org/10.1530/eje.0.1440037>)
- 17 Brunt LM, Lairmore TC, Doherty GM, Quasebarth MA, DeBenedetti M & Moley JF. Adrenalectomy for familial pheochromocytoma in the laparoscopic era. *Annals of Surgery* 2002 **235** 713–720; discussion 720-721. (<https://doi.org/10.1097/00000658-200205000-00014>)
- 18 Yip L, Lee JE, Shapiro SE, Waguespack SG, Sherman SI, Hoff AO, Gagel RF, Arens JF & Evans DB. Surgical management of hereditary pheochromocytoma. *Journal of the American College of Surgeons* 2004 **198** 525–534; discussion 534-535. (<https://doi.org/10.1016/j.jamcollsurg.2003.12.001>)
- 19 Patócs A, Karádi E, Tóth M, Varga I, Szücs N, Balogh K, Majnik J, Gláz E & Rác K. Clinical and biochemical features of sporadic and hereditary pheochromocytomas: an analysis of 41 cases investigated in a single endocrine centre. *European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP)* 2004 **13** 403–409. (<https://doi.org/10.1097/00008469-200410000-00008>)
- 20 Asari R, Scheuba C, Kaczirek K & Niederle B. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. *Archives of Surgery (Chicago, Ill.: 1960)* 2006 **141** 1199–1205; discussion 1205. (<https://doi.org/10.1001/archsurg.141.12.1199>)
- 21 Zhou Y, Zhao Y, Cui B, Gu L, Zhu S, Li J, Liu J, Yin M, Zhao T, Yin Z, *et al.* RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B. *Clinical Endocrinology* 2007 **67** 570–576. (<https://doi.org/10.1111/j.1365-2265.2007.02927.x>)
- 22 Rodriguez JM, Balsalobre M, Ponce JL, Ríos A, Torregrosa NM, Tebar J & Parrilla P. Pheochromocytoma in MEN 2A syndrome. Study of 54 patients. *World Journal of Surgery* 2008 **32** 2520–2526. (<https://doi.org/10.1007/s00268-008-9734-2>)
- 23 Mannelli M, Castellano M, Schiavi F, Filetti S, Giacchè M, Mori L, Pignataro V, Bernini G, Giacchè V, Bacca A, *et al.* Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. *The Journal of Clinical Endocrinology and Metabolism* 2009 **94** 1541–1547. (<https://doi.org/10.1210/jc.2008-2419>)
- 24 Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, Toledo SPA, Toledo RA, Tavares MR, Alevizaki M, *et al.* Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. *Human Mutation* 2011 **32** 51–58. (<https://doi.org/10.1002/humu.21385>)

- 25 Iacobone M, Schiavi F, Bottussi M, Taschin E, Bobisse S, Fassina A, Opocher G & Favia G. Is genetic screening indicated in apparently sporadic pheochromocytomas and paragangliomas? *Surgery* 2011 **150** 1194–1201. (<https://doi.org/10.1016/j.surg.2011.09.024>)
- 26 Scholten A, Vriens MR, Cromheecke GJE, Borel Rinkes IHM & Valk GD. Hemodynamic instability during resection of pheochromocytoma in MEN versus non-MEN patients. *European Journal of Endocrinology* 2011 **165** 91–96. (<https://doi.org/10.1530/EJE-11-0148>)
- 27 Qi XP, Chen XL, Ma JM, Du ZF, Fei J, Yang CP, Cheng J, Song QZ, Han JS, Jin HY, *et al.* RET proto-oncogene genetic screening of families with multiple endocrine neoplasia type 2 optimizes diagnostic and clinical management in China. *Thyroid: Official Journal of the American Thyroid Association* 2012 **22** 1257–1265. (<https://doi.org/10.1089/thy.2012.0134>)
- 28 Machens A, Lorenz K & Dralle H. Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening. *The Journal of Clinical Endocrinology and Metabolism* 2013 **98** E336-345. (<https://doi.org/10.1210/jc.2012-3192>)
- 29 Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, Cote G, Waguespack SG, Habra MA & Jimenez C. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. *The Journal of Clinical Endocrinology and Metabolism* 2013 **98** E1813-1819. (<https://doi.org/10.1210/jc.2013-1653>)
- 30 Imai T, Uchino S, Okamoto T, Suzuki S, Kosugi S, Kikumori T, Sakurai A, & MEN Consortium of Japan. High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. *European Journal of Endocrinology* 2013 **168** 683–687. (<https://doi.org/10.1530/EJE-12-1106>)
- 31 Castinetti F, Qi XP, Walz MK, Maia AL, Sansó G, Peczkowska M, Hasse-Lazar K, Links TP, Dvorakova S, Toledo RA, *et al.* Outcomes of adrenal-sparing surgery or total adrenalectomy in pheochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. *The Lancet. Oncology* 2014 **15** 648–655. ([https://doi.org/10.1016/S1470-2045\(14\)70154-8](https://doi.org/10.1016/S1470-2045(14)70154-8))
- 32 Korpershoek E, Petri BJ, Post E, Eijck CHJ van, Oldenburg RA, Belt EJT, Herder WW de, Krijger RR de & Dinjens WNM. Adrenal medullary hyperplasia is a precursor lesion for pheochromocytoma in MEN2 syndrome. *Neoplasia (New York, N.Y.)* 2014 **16** 868–873. (<https://doi.org/10.1016/j.neo.2014.09.002>)
- 33 Crona J, Nordling M, Maharjan R, Granberg D, Ståhlberg P, Hellman P & Björklund P. Integrative genetic characterization and phenotype correlations in pheochromocytoma and paraganglioma tumours. *PLoS One* 2014 **9** e86756. (<https://doi.org/10.1371/journal.pone.0086756>)
- 34 Ferreira CV, Siqueira DR, Romitti M, Ceolin L, Brasil BA, Meurer L, Capp C & Maia AL. Role of VEGF-A and its receptors in sporadic and MEN2-associated pheochromocytoma. *International Journal of Molecular Sciences* 2014 **15** 5323–5336. (<https://doi.org/10.3390/ijms15045323>)
- 35 Lee CH, Cheung CYY, Chow WS, Woo YC, Yeung CY, Lang BHH, Fong CHY, Kwok KHM, Chen SPL, Mak CM, *et al.* Genetics of Apparently Sporadic Pheochromocytoma and Paraganglioma in a Chinese

Population. *Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme* 2015 **47** 833–838. (<https://doi.org/10.1055/s-0035-1555955>)

- 36 Lang BHH, Yu HW, Lo CY, Lee KE, Garcia-Barcelo MM, Woo YC, Lee PCH, Wong KP, Tam PKH & Lam KSL. Bilateral Pheochromocytomas in MEN2A Syndrome: A Two-Institution Experience. *World Journal of Surgery* 2015 **39** 2484–2491. (<https://doi.org/10.1007/s00268-015-3117-2>)
- 37 Zhao JQ, Chen ZG & Qi XP. Molecular diagnosis and comprehensive treatment of multiple endocrine neoplasia type 2 in Southeastern Chinese. *Hereditary Cancer in Clinical Practice* 2015 **13** 5. (<https://doi.org/10.1186/s13053-015-0026-1>)
- 38 Rajan S, Zaidi G, Agarwal G, Mishra A, Agarwal A, Mishra SK & Bhatia E. Genotype-Phenotype Correlation in Indian Patients with MEN2-Associated Pheochromocytoma and Comparison of Clinico-Pathological Attributes with Apparently Sporadic Adrenal Pheochromocytoma. *World Journal of Surgery* 2016 **40** 690–696. (<https://doi.org/10.1007/s00268-015-3255-6>)
- 39 Puar T, Berkel A van, Gotthardt M, Havekes B, Hermus ARMM, Lenders JWM, Marken Lichtenbelt WD van, Xu Y, Brans B & Timmers HJLM. Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma. *The Journal of Clinical Endocrinology and Metabolism* 2016 **101** 224–232. (<https://doi.org/10.1210/jc.2015-3205>)
- 40 Kotecka-Blicharz A, Hasse-Lazar K, Jurecka-Lubieniecka B, Pawlaczek A, Oczko-Wojciechowska M, Bugajska B, Ledwon A, Król A, Michalik B & Jarzab B. Occurrence of pheochromocytoma tumours in RET mutation carriers - a single-centre study. *Endokrynologia Polska* 2016 **67** 54–58. (<https://doi.org/10.5603/EP.2016.0008>)
- 41 Mucha L, Leidig-Bruckner G, Frank-Raue K, Bruckner T, Kroiss M, Raue F, & German study group for rare thyroid cancer. Pheochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades. *Clinical Endocrinology* 2017 **87** 320–326. (<https://doi.org/10.1111/cen.13386>)
- 42 Sriprapradang C, Choopun K, Tunteeratum A & Sura T. Genotype-Phenotype Correlation in Patients With Germline Mutations of VHL, RET, SDHB, and SDHD Genes: Thai Experience. *Clinical Medicine Insights. Endocrinology and Diabetes* 2017 **10** 1179551417705122. (<https://doi.org/10.1177/1179551417705122>)
- 43 Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJLM, Fassnacht M, Klink B, Lodish M, Stratakis CA, et al. Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. *The Journal of Clinical Endocrinology and Metabolism* 2017 **102** 1122–1132. (<https://doi.org/10.1210/jc.2016-3829>)
- 44 Sbardella E, Cranston T, Isidori AM, Shine B, Pal A, Jafar-Mohammadi B, Sadler G, Mihai R & Grossman AB. Routine genetic screening with a multi-gene panel in patients with pheochromocytomas. *Endocrine* 2018 **59** 175–182. (<https://doi.org/10.1007/s12020-017-1310-9>)
- 45 Stenman A, Zedenius J & Juhlin CC. Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms. *Langenbeck's Archives of Surgery* 2018 **403** 785–790. (<https://doi.org/10.1007/s00423-018-1679-9>)

- 46 Makri A, Akshintala S, Derse-Anthony C, Del Rivero J, Widemann B, Stratakis CA, Glod J & Lodish M. Pheochromocytoma in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B. *The Journal of Clinical Endocrinology and Metabolism* 2019 **104** 7–12. (<https://doi.org/10.1210/jc.2018-00705>)
- 47 Castinetti F, Waguespack SG, Machens A, Uchino S, Hasse-Lazar K, Sanso G, Else T, Dvorakova S, Qi XP, Elisei R, *et al.* Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. *The Lancet. Diabetes & Endocrinology* 2019 **7** 213–220. ([https://doi.org/10.1016/S2213-8587\(18\)30336-X](https://doi.org/10.1016/S2213-8587(18)30336-X))
- 48 Kittah NE, Gruber LM, Bancos I, Hamidi O, Tamhane S, Iñiguez-Ariza N, Babovic-Vuksanovic D, Thompson GB, Lteif A, Young WF, *et al.* Bilateral pheochromocytoma: Clinical characteristics, treatment and longitudinal follow-up. *Clinical Endocrinology* 2020 **93** 288–295. (<https://doi.org/10.1111/cen.14222>)
- 49 Ma X, Li M, Tong A, Wang F, Cui Y, Zhang X, Zhang Y, Chen S & Li Y. Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma: A Single Center Study. *Frontiers in Endocrinology* 2020 **11** 574662. (<https://doi.org/10.3389/fendo.2020.574662>)
- 50 Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, *et al.* Genetic testing in pheochromocytoma or functional paraganglioma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 2005 **23** 8812–8818. (<https://doi.org/10.1200/JCO.2005.03.1484>)
- 51 Bausch B, Borozdin W, Neumann HPH, & European-American Pheochromocytoma Study Group. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. *The New England Journal of Medicine* 2006 **354** 2729–2731. (<https://doi.org/10.1056/NEJMc066006>)
- 52 Zinamosca L, Petramala L, Cotesta D, Marinelli C, Schina M, Cianci R, Giustini S, Sciomer S, Anastasi E, Calvieri S, *et al.* Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects. *Archives of Dermatological Research* 2011 **303** 317–325. (<https://doi.org/10.1007/s00403-010-1090-z>)
- 53 Shinall MC & Solórzano CC. Pheochromocytoma in Neurofibromatosis Type 1: When Should it Be Suspected? *Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists* 2014 **20** 792–796. (<https://doi.org/10.4158/EP13417.OR>)
- 54 Képénékian L, Mognetti T, Lifante JC, Giraudet AL, Houzard C, Pinson S, Borson-Chazot F & Combemale P. Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1. *European Journal of Endocrinology* 2016 **175** 335–344. (<https://doi.org/10.1530/EJE-16-0233>)
- 55 Moramarco J, El Ghorayeb N, Dumas N, Nolet S, Boulanger L, Burnichon N, Lacroix A, Elhaffaf Z, Gimenez Roqueplo AP, Hamet P, *et al.* Pheochromocytomas are diagnosed incidentally and at older age in neurofibromatosis type 1. *Clinical Endocrinology* 2017 **86** 332–339. (<https://doi.org/10.1111/cen.13265>)

- 56 Gruber LM, Erickson D, Babovic-Vuksanovic D, Thompson GB, Young WF & Bancos I. Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1. *Clinical Endocrinology* 2017 **86** 141–149. (<https://doi.org/10.1111/cen.13163>)
- 57 Petr EJ & Else T. Pheochromocytoma and Paraganglioma in Neurofibromatosis type 1: frequent surgeries and cardiovascular crises indicate the need for screening. *Clinical Diabetes and Endocrinology* 2018 **4** 15. (<https://doi.org/10.1186/s40842-018-0065-4>)
- 58 Al-Sharefi A, Javaid U, Perros P, Ealing J, Truran P, Nag S, Kamaruddin S, Abouglila K, Cains F, Lewis L, *et al.* Clinical Presentation and Outcomes of Pheochromocytomas/Paragangliomas in Neurofibromatosis Type 1. *European Endocrinology* 2019 **15** 95–100. (<https://doi.org/10.17925/EE.2019.15.2.95>)
- 59 Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, Lechleiter JD, Sass M, Aronin N, Schiavi F, *et al.* Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. *Nature genetics* 2010 **42** 229–233. (<https://doi.org/10.1038/ng.533>)
- 60 Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Pérez L, King EE, Toledo RA, Ercolino T, Rapizzi E, Ricketts CJ, *et al.* Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. *JAMA* 2010 **304** 2611–2619. (<https://doi.org/10.1001/jama.2010.1830>)
- 61 Neumann HPH, Sullivan M, Winter A, Malinoc A, Hoffmann MM, Boedeker CC, Bertz H, Walz MK, Moeller LC, Schmid KW, *et al.* Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. *The Journal of Clinical Endocrinology and Metabolism* 2011 **96** E1279–1282. (<https://doi.org/10.1210/jc.2011-0114>)
- 62 Takeichi N, Midorikawa S, Watanabe A, Naing BT, Tamura H, Wakakuri-Kano T, Ishizaki A, Sugihara H, Nissato S, Saito Y, *et al.* Identical germline mutations in the TMEM127 gene in two unrelated Japanese patients with bilateral pheochromocytoma. *Clinical Endocrinology* 2012 **77** 707–714. (<https://doi.org/10.1111/j.1365-2265.2012.04421.x>)
- 63 Abermil N, Guillaud-Bataille M, Burnichon N, Venisse A, Manivet P, Guignat L, Drui D, Chupin M, Josseume C, Affres H, *et al.* TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. *The Journal of Clinical Endocrinology and Metabolism* 2012 **97** E805–809. (<https://doi.org/10.1210/jc.2011-3360>)
- 64 Lefebvre S, Borson-Chazot F, Boutry-Kryza N, Wion N, Schillo F, Peix JL, Brunaud L, Finat A, Calender A & Giraud S. Screening of mutations in genes that predispose to hereditary paragangliomas and pheochromocytomas. *Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme* 2012 **44** 334–338. (<https://doi.org/10.1055/s-0032-1306308>)
- 65 Toledo SPA, Lourenço DM, Sekiya T, Lucon AM, Baena MES, Castro CC, Bortolotto LA, Zerbini MCN, Siqueira SAC, Toledo RA, *et al.* Penetrance and clinical features of pheochromocytoma in a six-generation family carrying a germline TMEM127 mutation. *The Journal of Clinical Endocrinology and Metabolism* 2015 **100** E308–318. (<https://doi.org/10.1210/jc.2014-2473>)
- 66 Patócs A, Lendvai NK, Butz H, Liko I, Sapi Z, Szucs N, Toth G, Grolmusz VK, Igaz P, Toth M, *et al.* Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome. *Pathology oncology research: POR* 2016 **22** 673–679. (<https://doi.org/10.1007/s12253-016-0050-0>)

- 67 Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, Wellner U, Malinoc A, Taschin E, Barbon G, *et al.* Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention. *JAMA oncology* 2017 **3** 1204–1212. (<https://doi.org/10.1001/jamaoncol.2017.0223>)
- 68 Eijkelenkamp K, Olderde-Berends MJW, Luijt RB van der, Robledo M, Dooren M van, Feelders RA, Vries J de, Kerstens MN, Links TP & Horst-Schrivers ANA van der. Homozygous TMEM127 mutations in 2 patients with bilateral pheochromocytomas. *Clinical Genetics* 2018 **93** 1049–1056. (<https://doi.org/10.1111/cge.13202>)
- 69 Armaiz-Pena G, Flores SK, Cheng ZM, Zhang X, Esquivel E, Poullard N, Vaidyanathan A, Liu Q, Michalek J, Santillan-Gomez AA, *et al.* Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update. *The Journal of Clinical Endocrinology and Metabolism* 2021 **106** e350–e364. (<https://doi.org/10.1210/clinem/dgaa741>)
- 70 Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, Landa I, Leandro-García LJ, Letón R, Honrado E, Ramos-Medina R, Caronia D, Pita G, *et al.* Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. *Nature Genetics* 2011 **43** 663–667. (<https://doi.org/10.1038/ng.861>)
- 71 Burnichon N, Cascón A, Schiavi F, Morales NP, Comino-Méndez I, Abermil N, Inglada-Pérez L, Cubas AA de, Amar L, Barontini M, *et al.* MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* 2012 **18** 2828–2837. (<https://doi.org/10.1158/1078-0432.CCR-12-0160>)
- 72 Korpershoek E, Koffy D, Eussen BH, Oudijk L, Papathomas TG, Nederveen FH van, Belt EJT, Franssen GJH, Restuccia DFJ, Krol NMG, *et al.* Complex MAX Rearrangement in a Family With Malignant Pheochromocytoma, Renal Oncocytoma, and Erythrocytosis. *The Journal of Clinical Endocrinology and Metabolism* 2016 **101** 453–460. (<https://doi.org/10.1210/jc.2015-2592>)
- 73 Daly AF, Castermans E, Oudijk L, Guitelman MA, Beckers P, Potorac I, Neggers SJM, Sacre N, Lely AJ van der, Bours V, *et al.* Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. *Endocrine-Related Cancer* 2018 **25** L37–L42. (<https://doi.org/10.1530/ERC-18-0065>)
- 74 Seabrook AJ, Harris JE, Velosa SB, Kim E, McInerney-Leo AM, Dwight T, Hockings JI, Hockings NG, Kirk J, Leo PJ, *et al.* Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5? *The Journal of Clinical Endocrinology and Metabolism* 2021 **106** 1163–1182. (<https://doi.org/10.1210/clinem/dgaa957>)

